Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$46.74
-0.7%
$59.04
$45.52
$77.32
$8.50B0.01981,873 shs183,881 shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
$64.41
$4.12B0.772.76 million shsN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$172.36
+0.0%
$171.30
$21.83
$172.46
$6.58B1.421.09 million shs1.99 million shs
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$237.78
+1.6%
$232.07
$204.44
$261.54
$11.19B0.52430,936 shs80,214 shs
Zai Lab Limited stock logo
ZLAB
Zai Lab
$15.37
+2.5%
$17.75
$13.48
$39.50
$1.52B1.1630,513 shs132,058 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Legend Biotech Co. stock logo
LEGN
Legend Biotech
+1.88%-8.99%-19.06%-22.59%-32.48%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%+37.70%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00%0.00%0.00%0.00%+72.43%
United Therapeutics Co. stock logo
UTHR
United Therapeutics
-1.63%-0.43%-1.61%+7.47%+1.43%
Zai Lab Limited stock logo
ZLAB
Zai Lab
+6.54%+5.56%-7.35%-34.85%-58.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.4365 of 5 stars
4.51.00.00.01.91.70.6
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.1726 of 5 stars
1.10.00.04.70.00.00.6
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.5122 of 5 stars
1.10.00.04.80.01.70.6
United Therapeutics Co. stock logo
UTHR
United Therapeutics
4.76 of 5 stars
4.40.00.04.63.23.31.9
Zai Lab Limited stock logo
ZLAB
Zai Lab
1.7076 of 5 stars
3.52.00.00.01.71.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.92
Moderate Buy$83.2678.13% Upside
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
2.21
Hold$60.002.21% Upside
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
2.25
Hold$162.44-5.75% Downside
United Therapeutics Co. stock logo
UTHR
United Therapeutics
2.89
Moderate Buy$294.2523.75% Upside
Zai Lab Limited stock logo
ZLAB
Zai Lab
3.00
Buy$64.22317.85% Upside

Current Analyst Ratings

Latest MRTX, UTHR, RETA, LEGN, and ZLAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
4/17/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Perform ➝ Sector Outperform$65.00
4/16/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
4/3/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$82.00
4/1/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
3/18/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$87.00
3/18/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$76.00 ➝ $81.00
3/13/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$86.00
3/7/2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$85.00
3/7/2024
United Therapeutics Co. stock logo
UTHR
United Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$309.00 ➝ $325.00
2/29/2024
Zai Lab Limited stock logo
ZLAB
Zai Lab
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$123.00 ➝ $66.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$285.14M29.82N/AN/A$6.88 per share6.79
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$23.48M280.05N/AN/A($1.79) per share-96.29
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$2.33B4.81$22.08 per share10.77$127.35 per share1.87
Zai Lab Limited stock logo
ZLAB
Zai Lab
$266.72M5.72N/AN/A$8.05 per share1.91

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$1.48N/A584.25N/A-181.75%-37.19%-25.34%5/13/2024 (Confirmed)
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
-$311.90MN/A0.00N/AN/AN/A-922.50%-73.39%N/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$984.80M$19.8411.989.70N/A42.31%17.72%14.47%5/1/2024 (Estimated)
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$334.62M-$3.45N/AN/AN/A-125.46%-37.07%-30.72%5/8/2024 (Confirmed)

Latest MRTX, UTHR, RETA, LEGN, and ZLAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.23N/A+$0.23N/AN/AN/A  
5/8/2024N/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$0.83N/A+$0.83N/AN/AN/A  
3/11/2024Q4 2023
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.70-$0.40+$0.30-$0.40$95.63 million$76.50 million    
2/27/2024Q4 2023
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$0.87-$0.98-$0.11-$0.98$70.41 million$65.83 million
2/21/202412/31/2023
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$4.28$4.36+$0.08$4.36$575.01 million$614.70 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.22
6.92
6.83
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.84
3.21
3.19
United Therapeutics Co. stock logo
UTHR
United Therapeutics
0.05
4.41
4.28
Zai Lab Limited stock logo
ZLAB
Zai Lab
N/A
4.63
4.41

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
94.08%
Zai Lab Limited stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.02%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
26.80%
United Therapeutics Co. stock logo
UTHR
United Therapeutics
12.50%
Zai Lab Limited stock logo
ZLAB
Zai Lab
5.23%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,800181.91 million181.88 millionOptionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionOptionable
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
32138.15 million27.93 millionOptionable
United Therapeutics Co. stock logo
UTHR
United Therapeutics
1,16847.06 million41.18 millionOptionable
Zai Lab Limited stock logo
ZLAB
Zai Lab
2,17599.21 million94.02 millionOptionable

MRTX, UTHR, RETA, LEGN, and ZLAB Headlines

SourceHeadline
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07
marketbeat.com - April 22 at 12:00 PM
Zai Lab Ltd. ADRZai Lab Ltd. ADR
wsj.com - April 21 at 8:26 PM
Zai Lab Limited (ZLAB)Zai Lab Limited (ZLAB)
finance.yahoo.com - April 19 at 1:02 AM
Zai Lab (NASDAQ:ZLAB)  Shares Down 2.4% Zai Lab (NASDAQ:ZLAB) Shares Down 2.4%
marketbeat.com - April 17 at 11:58 AM
Genesis Investment Management LLP Sells 339,503 Shares of Zai Lab Limited (NASDAQ:ZLAB)Genesis Investment Management LLP Sells 339,503 Shares of Zai Lab Limited (NASDAQ:ZLAB)
marketbeat.com - April 17 at 11:55 AM
A Risky Bet: Zai Labs Uncertain FutureA Risky Bet: Zai Lab's Uncertain Future
seekingalpha.com - April 16 at 7:13 PM
Zai Lab (NASDAQ:ZLAB) Sets New 52-Week Low at $14.01Zai Lab (NASDAQ:ZLAB) Sets New 52-Week Low at $14.01
marketbeat.com - April 16 at 1:41 PM
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
businesswire.com - April 15 at 7:30 AM
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
businesswire.com - April 15 at 7:30 AM
Zai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesZai Lab Statement on Executive Management Team’s Agreement on Share Activities
finance.yahoo.com - April 11 at 12:31 PM
Zai Lab Statement on Executive Management Teams Agreement on Share ActivitiesZai Lab Statement on Executive Management Team's Agreement on Share Activities
businesswire.com - April 11 at 7:30 AM
Zai Lab (NASDAQ:ZLAB) Reaches New 52-Week Low at $15.13Zai Lab (NASDAQ:ZLAB) Reaches New 52-Week Low at $15.13
marketbeat.com - April 10 at 3:24 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
markets.businessinsider.com - April 9 at 12:42 PM
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.49Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $15.49
marketbeat.com - April 9 at 11:25 AM
Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $13,241.15 in StockZai Lab Limited (NASDAQ:ZLAB) CFO Sells $13,241.15 in Stock
insidertrades.com - April 6 at 7:57 AM
Frazor Titus Edmondson III Sells 885 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockFrazor Titus Edmondson III Sells 885 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock
insidertrades.com - April 4 at 7:09 AM
Zai Lab Limited (NASDAQ:ZLAB) Insider Sells $14,292.75 in StockZai Lab Limited (NASDAQ:ZLAB) Insider Sells $14,292.75 in Stock
marketbeat.com - April 4 at 12:21 AM
Zai Lab (NASDAQ:ZLAB) Sets New 12-Month Low at $15.53Zai Lab (NASDAQ:ZLAB) Sets New 12-Month Low at $15.53
marketbeat.com - April 3 at 12:47 PM
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
businesswire.com - April 2 at 7:30 AM
Zai Lab reports Krazati lung cancer study meets primary endpointZai Lab reports Krazati lung cancer study meets primary endpoint
msn.com - April 1 at 4:01 PM
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years agoShareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
finance.yahoo.com - April 1 at 4:01 PM
One Good, One Bad News For Bristol Myers Squibbs Marketed Drugs: DetailsOne Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
msn.com - April 1 at 11:01 AM
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
finance.yahoo.com - April 1 at 11:01 AM
Novocure climbs after late-stage win for lung cancer therapyNovocure climbs after late-stage win for lung cancer therapy
msn.com - March 27 at 9:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Legend Biotech logo

Legend Biotech

NASDAQ:LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Mirati Therapeutics logo

Mirati Therapeutics

NASDAQ:MRTX
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Reata Pharmaceuticals logo

Reata Pharmaceuticals

NASDAQ:RETA
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
United Therapeutics logo

United Therapeutics

NASDAQ:UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Zai Lab logo

Zai Lab

NASDAQ:ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.